SEC Form 4
Rani Therapeutics Holdings, Inc. (RANI) insider trading
In the 12 months to Oct 26, 2026, 2 RANI insiders reported open-market purchases of $1.3M across 3 filings; no open-market sales were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $0
- 0 filings · 0 insiders
- Open-market purchases
- $1.3M
- 3 filings
Who traded RANI, and when
- Purchase
RANI daily close from Oct 27, 2025 to Oct 26, 2026, between $0.59 and $2.50, last $0.59. 0 sale and 3 purchase filings by 2 insiders, marked at their filing dates. Mir A. Imran, Director: bought $1.3M across 2 filings, first filed Oct 27, 2025, last Jul 23, 2026. Talat Imran, Chief Executive Officer: bought $25.2K across 1 filing, first filed Jul 21, 2026, last Jul 21, 2026.
Largest mark · tap a row for others
Mir A. Imran · Director
Purchase $1,260,417
2,083,334 shares at $0.61 avg
Filed Oct 27, 2025 · traded Oct 23
Close on filing date $1.78
Mir A. Imran · Director
Director
$1.3M boughtTalat Imran · Chief Executive Officer
Chief Executive Officer
$25.2K boughtOpen-market trades
3 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Mir A. Imran | Director | — | $1.3M | 2 | — | |
| Talat Imran | Chief Executive Officer | — | $25.2K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Mir A. Imran Director | Purchase | 36,000 | $0.69 | $24.8K | 2,119,334 | |
traded | Talat Imran Chief Executive Officer | Purchase | 35,000 | $0.72 | $25.2K | 469,736 | |
traded | Mir A. Imran Director | Purchase | 2,083,334 | $0.61 | $1.3M | 2,083,334 |
GET /stocks/filings/vX/form-4?tickers=RANI&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RANI"
],
"issuer_cik": "0001856725",
"owner_cik": "0001031686",
"accession_number": "0001031686-26-000006",
"form_type": "4",
"filing_date": "2026-07-23",
"period_of_report": "2026-07-21",
"issuer_name": "Rani Therapeutics Holdings, Inc.",
"issuer_trading_symbol": "RANI",
"owner_name": "IMRAN MIR A",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": true,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-21",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 36000,
"transaction_price_per_share": 0.69,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 2119334,
"transaction_value": 24839.999999999996,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.688 to $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"RANI"
],
"issuer_cik": "0001856725",
"owner_cik": "0001869579",
"accession_number": "0001869579-26-000007",
"form_type": "4",
"filing_date": "2026-07-21",
"period_of_report": "2026-07-17",
"issuer_name": "Rani Therapeutics Holdings, Inc.",
"issuer_trading_symbol": "RANI",
"owner_name": "Imran Talat",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Executive Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-07-17",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 35000,
"transaction_price_per_share": 0.7198,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 469736,
"transaction_value": 25193,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 11 records
- Tax withholding9 records
- Tax withholding (sold to cover)2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Rani Therapeutics Holdings, Inc.'s CEO sold stock?
No. Talat Imran (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is RANI’s insider data?
These are RANI Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track RANI insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RANI every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.